FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...

Q3 2025 Management View Jay Short, Co-Founder, CEO & Chairman, emphasized that BioAtla is "currently in advanced stages to ...

Q3 2025 Earnings Call Transcript November 14, 2025 P3 Health Partners Inc. misses on earnings expectations. Reported EPS is $ ...

John Kao: And thank you for joining us on our third quarter earnings conference call. For the third quarter of 2025, we exceeded the high end of each of our guidance metrics. Health plan membership of ...

Net order intake was approximately $19,000,000 and we achieved a positive gross margin of 15%. While this margin result may ...

Alignment Healthcare LLC reported its Q3 2025 earnings, surpassing expectations with an EPS of $0.02 against a forecasted loss of $0.08. The company also reported a revenue of $994 million, slightly ...

Good afternoon, and welcome to Alignment Healthcare's Fourth Quarter 2024 Earnings Conference Call and Webcast. [Operator Instructions]. Please note that this event is being recorded. Leading today's ...